Sopharma AD
Market Cap
лв457.9m
Last Updated
2021/06/17 21:45 UTC
Data Sources
Company Financials +
Executive Summary
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria, rest of Europe, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Very undervalued average dividend payer.
Similar Companies
Share Price & News
How has Sopharma AD's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SFA is less volatile than 75% of BG stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: SFA's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
1.7%
SFA
1.7%
BG Pharmaceuticals
0.4%
BG Market
1 Year Return
14.8%
SFA
2.1%
BG Pharmaceuticals
21.1%
BG Market
Return vs Industry: SFA exceeded the BG Pharmaceuticals industry which returned 2.1% over the past year.
Return vs Market: SFA underperformed the BG Market which returned 21.1% over the past year.
Shareholder returns
| SFA | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.7% | 1.7% | 0.4% |
| 30 Day | 9.0% | 6.9% | 0.4% |
| 90 Day | 10.3% | 11.3% | -1.8% |
| 1 Year | 16.4%14.8% | 5.4%2.1% | 22.7%21.1% |
| 3 Year | -6.2%-14.2% | 45.2%29.2% | 18.7%16.7% |
| 5 Year | 57.8%37.4% | 54.8%28.6% | 46.8%35.1% |
Long-Term Price Volatility Vs. Market
How volatile is Sopharma AD's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
What Kind Of Investors Own Most Of Sopharma AD (BUL:SFA)?2 months ago | Simply Wall St
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet3 months ago | Simply Wall St
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth WatchingValuation
Is Sopharma AD undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SFA (BGN3.66) is trading below our estimate of fair value (BGN32.65)
Significantly Below Fair Value: SFA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SFA is good value based on its PE Ratio (14.2x) compared to the European Pharmaceuticals industry average (26.8x).
PE vs Market: SFA is good value based on its PE Ratio (14.2x) compared to the BG market (25.8x).
Price to Earnings Growth Ratio
PEG Ratio: SFA is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: SFA is good value based on its PB Ratio (0.8x) compared to the XE Pharmaceuticals industry average (3.5x).
Future Growth
How is Sopharma AD forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
15.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SFA's forecast earnings growth (15.7% per year) is above the savings rate (1.3%).
Earnings vs Market: SFA's earnings (15.7% per year) are forecast to grow faster than the BG market (15.2% per year).
High Growth Earnings: SFA's earnings are forecast to grow, but not significantly.
Revenue vs Market: SFA's revenue (4.1% per year) is forecast to grow slower than the BG market (10.9% per year).
High Growth Revenue: SFA's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SFA's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Sopharma AD performed over the past 5 years?
11.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SFA has a high level of non-cash earnings.
Growing Profit Margin: SFA's current net profit margins (2.2%) are lower than last year (6.1%).
Past Earnings Growth Analysis
Earnings Trend: SFA's earnings have grown by 11.1% per year over the past 5 years.
Accelerating Growth: SFA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SFA had negative earnings growth (-60.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.1%).
Return on Equity
High ROE: SFA's Return on Equity (5.3%) is considered low.
Financial Health
How is Sopharma AD's financial position?
Financial Position Analysis
Short Term Liabilities: SFA's short term assets (BGN599.6M) exceed its short term liabilities (BGN513.0M).
Long Term Liabilities: SFA's short term assets (BGN599.6M) exceed its long term liabilities (BGN121.6M).
Debt to Equity History and Analysis
Debt Level: SFA's debt to equity ratio (55.3%) is considered high.
Reducing Debt: SFA's debt to equity ratio has increased from 53% to 55.3% over the past 5 years.
Debt Coverage: SFA's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: SFA's interest payments on its debt are well covered by EBIT (6.7x coverage).
Balance Sheet
Dividend
What is Sopharma AD current dividend yield, its reliability and sustainability?
3.85%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SFA's dividend (3.83%) is higher than the bottom 25% of dividend payers in the BG market (1.61%).
High Dividend: SFA's dividend (3.83%) is low compared to the top 25% of dividend payers in the BG market (5.22%).
Stability and Growth of Payments
Stable Dividend: SFA's dividend payments have been volatile in the past 10 years.
Growing Dividend: SFA's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (42.8%), SFA's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SFA's dividends in 3 years are forecast to be well covered by earnings (34.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
лв655k
CEO Compensation
CEO
Ognian Donev (64 yo)
no data
Tenure
лв655,309
Compensation
Mr. Ognian Ivanov Donev, D.Sc. (Econ.), Ph.D., serves as the Executive Chairman at Sopharma AD and Sopharma Trading AD. Mr. Donev serves as Managing Director and Chief Executive Officer of Sopharma AD. He ...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sopharma AD's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sopharma AD
- Ticker: SFA
- Exchange: BUL
- Founded: 1933
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: лв457.863m
- Shares outstanding: 125.79m
- Website: https://www.sopharmagroup.com
Number of Employees
Location
- Sopharma AD
- 16 Iliensko shosse street
- Sofia
- Bulgaria
Listings
Biography
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veteri...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/17 21:45 |
| End of Day Share Price | 2021/06/17 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.